Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

0.95USD
3:59pm EST
Change (% chg)

$0.02 (+2.15%)
Prev Close
$0.93
Open
$0.94
Day's High
$1.08
Day's Low
$0.88
Volume
216,830
Avg. Vol
30,521
52-wk High
$5.07
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Mereo Biopharma Proposes Combination Of Mereo & Oncomed
Wednesday, 5 Dec 2018 08:09am EST 

Dec 5 (Reuters) - Mereo BioPharma Group plc ::PROPOSED COMBINATION OF MEREO AND ONCOMED.ENLARGED GROUP EXPECTS TO LAUNCH NEW NASDAQ-LISTED ADR PROGRAMME.TO ISSUE ABOUT 23.7 MLN NEW SHARES WHICH WILL BE DEPOSITED WITH A DEPOSITARY IN ORDER TO ISSUE MEREO ADRS TO ONCOMED SHAREHOLDERS.CURRENT ONCOMED SHAREHOLDERS EXPECTED TO OWN ABOUT 25% OF ISSUED SHARE CAPITAL OF ENLARGED GROUP AFTER DEAL CLOSE.ONCOMED SHAREHOLDERS TO RECEIVE CVRS REPRESENTING RIGHT TO RECEIVE FUTURE CONDITIONAL CASH PAYMENTS.SHARES UNDERLYING MEREO ADRS TO BE ISSUED IN EXCHANGE FOR EACH ONCOMED SHARE REPRESENT AGGREGATE VALUE OF ABOUT $57.4 MLN.ONCOMED SHAREHOLDERS WILL ALSO RECEIVE ADDITIONAL ADRS BASED ON ACHIEVEMENT OF CERTAIN MILESTONES RELATING TO ONCOMED ASSETS.FOLLOWING DEAL COMPLETION, MEREO BOARD WILL BE EXPANDED TO 10 PERSONS.EXISTING MEREO DIRECTORS WILL CONTINUE TO SERVE IN THEIR CURRENT POSITIONS.DEAL TO BE EFFECTED BY ALL-STOCK TRANSACTION PLUS ISSUANCE OF CONTINGENT VALUE RIGHTS; COMPLETION EXPECTED H1 2019.  Full Article

Oncomed Says Chief Executive Officer Paul Hastings Has Resigned
Thursday, 4 Jan 2018 04:02pm EST 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED.ONCOMED PHARMACEUTICALS INC - IN INTERIM, OFFICE OF PRESIDENT WILL CONTINUE TO PERFORM DUTIES OF PRESIDENT AND CEO.ONCOMED PHARMACEUTICALS INC - BOARD OF DIRECTORS HAS APPOINTED PERRY KARSEN AS CHAIRMAN OF BOARD.  Full Article

OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln
Thursday, 4 Jan 2018 04:02pm EST 

Jan 4 (Reuters) - Oncomed Pharmaceuticals Inc ::ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM.ONCOMED PHARMACEUTICALS INC - YEAR-END 2017 CASH BALANCE OF $103.1 MILLION.ONCOMED PHARMACEUTICALS INC - ‍PRESENTATION OF CLINICAL DATA ON PHASE 1 PROGRAMS EXPECTED IN 2018​.ONCOMED PHARMACEUTICALS - CURRENT CASH ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 2019.ONCOMED - ESTIMATES 2018 OPERATING CASH BURN TO BE LESS THAN $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONES/OPT-INS.ONCOMED - ‍TO INITIATE PHASE 1B PORTION OF ITS ANTI-TIGIT TRIAL TO STUDY ANTI-TIGIT IN COMBINATION WITH ANTI-PD1 IN FIRST HALF OF 2018​.  Full Article

Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 6 Dec 2017 08:39am EST 

Dec 6 (Reuters) - PERCEPTIVE ADVISORS LLC :PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC <<>>AS OF NOV 6 - SEC FILING.  Full Article

Oncomed posts Q3 loss per share $0.28
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Oncomed Pharmaceuticals Inc :Oncomed announces third quarter 2017 financial results and operational highlights.Q3 loss per share $0.28.Q3 revenue $5.1 million versus $5.9 million.Oncomed Pharmaceuticals Inc - ‍anticipates 2017 full-year cash utilization will be approximately $90 million​.Oncomed says current cash balance sufficient to fund pipeline development & operations through Q3 2019, before considering potential opt-in milestones​.Oncomed Pharmaceuticals - ‍now plans to initiate Phase 1B portion of anti-tigit trial to study anti-tigit in combination with anti-PD1 in H1 2018​.  Full Article